Lv2
118 积分 2024-07-15 加入
Abstract 3799: HER3 inhibition sensitizes metastatic colorectal and pancreatic cancer to immunotherapy
3个月前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
5个月前
已完结
Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer
6个月前
已完结
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer
7个月前
已完结
The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer
8个月前
已完结
Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection
8个月前
已完结
HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients
9个月前
已完结
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
10个月前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
10个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
10个月前
已完结
皖公网安备34019202002308
